Naples

• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• Ertugliflozin Pediatric Study Ended
  2022-501085-21-00 5 2019-11-29 Type 2 Diabetes Mellitus
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended
  2024-515929-28-00 4 2019-08-02 Non-small Cell Lung Cancer
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended
  2023-508832-68-00 9 2019-03-28 Recurrent or stage IVB cervical cancer
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended
  2023-508207-21-00 9 2019-02-08 Advanced Malignant Tumors
• Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry … Ended
  2024-516735-27-00 5 2019-01-31 Fabry disease (α-galactosidase A deficiency)
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• Olaparib Monotherapy in HRRm or HRD Positive Cancer Ended
  2022-500797-34-00 4 2018-12-17 Treatment of participants with positive cancer for HRRm or HRD.
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended
  2022-502938-30-00 5 2018-12-10 Moderate and Severe Atopic Dermatitis
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma Ended
  2024-517290-24-00 4 2017-12-19 Previously untreated advanced uveal melanoma (UM)
• Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc … Ended
  2024-513167-68-00 5 2017-11-29 endometrial cancer
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 5 2017-10-27 Advanced or Metastatic Renal Cell Carcinoma
• This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body a … Ended
  2023-509969-20-00 1 2017-07-24 Part C: advanced or unresectable STs (Spain only)
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma

Showing 1,129–1,152 of 1,177 trials